In this Medscape commentary, Dr. Scott Kopetz of MD Anderson unpacks the rising role of ctDNA in colorectal cancer. Unlike traditional risk factors, ctDNA offers a real-time snapshot of tumor biology with powerful prognostic value. From guiding adjuvant therapy decisions in stage 2 and 3 disease to detecting recurrence months before imaging, the test is reshaping how oncologists think about surveillance and trial design. With sensitivity still evolving and novel therapies on the horizon, is ctDNA about to become the new backbone of CRC management?
Trending
- 7 HLTH Announcements You Don’t Want to Miss (MedCity News)
- Practical Tips for Contracting, Part 2 (GI & Endoscopy News)
- GRAIL PATHFINDER 2 Results Show Galleri® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings (GRAIL)
- Eliminating Cost Sharing Boosted Follow-Up Colonoscopy Rates (AJMC)
- St. Charles Health System Taps WovenX to Transform GI Access and Optimize Capacity (PR Newswire)
- United Digestive adds 5 gastroenterologists in 3 months (Becker’s GI & Endoscopy)
- Negotiated Prices for Large Insurers and Regional Differences in Employed Cardiology and GI Groups Revealed (Medscape)
- Health care in the USA: money has become the mission (The Lancet)
